A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the cancer's energy-creating mechanism, according to a study. Prostate cancer burns fat to create energy. Researchers discovered that blocking this metabolism process makes an androgen treatment known as Xtandi (enzalutamide) more effective against castration-resistant prostate cancer, or CRPC. The preclinical-trial study, conducted in prostate cancer cells grown in a lab and in animal models, showed that a CPT1A inhibitor called ranolazine works in synergy with Xtandi to reduce tumor growth. The research, "